EUVIMEDOpdag EUVIMED
Systematische ÜbersichtOpen access · CC BY-NC-ND 4.0

Systematic Review of Immune and Symptomatic Treatments for Stiff‐Person Syndrome

Timothée Lenglet iD, Jérôme Honnorat, Shahram Attarian iD

European Journal of Neurology · 2025-11 · 32 (11)

DOI: 10.1111/ene.70435 ↗

At a glance

Systematische Übersicht in European Journal of Neurology, published online on 2025-11-22. Written by Timothée Lenglet and 2 co-authors. Institution: Département de Neurophysiologie, Groupe Hospitalier Pitié-Salpêtrière, APHP, Paris, France. Major MEDLINE topics: Stiff-Person Syndrome, Immunotherapy. Cited 5 times so far (Crossref); 48 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: LFB.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background and Purpose This systematic review evaluated the effectiveness and safety of immune and symptomatic treatments in patients with stiff‐person syndrome (SPS).

Methods

A systematic search of PubMed, Embase, and the Cochrane Library was conducted up to September 30, 2024 in accordance with the PRISMA guidelines. All studies that involve SPS patients treated with symptomatic pharmacotherapy or immunotherapy and where the outcome is reported were included in the initial screening. Case reports were excluded. Two independent reviewers carried out study selection, bias assessment with the Murad et al. tool for case series, ROBINS‐I for observational studies or RoB‐2 for randomised trials, and data extraction into a predefined template. All available efficacy and safety data were recorded. A narrative synthesis was conducted to address the heterogeneity of the studies.

Results

Thirty‐six studies were included. Most of the included studies consisted of small‐scale studies, with 21 case series, 10 cohort studies and only five randomised controlled trials. Outcome assessments varied across the reviewed studies. Most studies assessed measures with subjective self‐report and/or through clinical observations. Spasms and stiffness were assessed in around 60% of studies. Walking ability and pain were evaluated in less than half of studies. Only 10 (28%) studies assessed functional improvement using a valid and reliable tool. The present review highlights the paucity of data and the heterogeneity in SPS treatment responses and underscores the need for individualised therapeutic strategies.

Conclusions

Standardised assessment methods in clinical practice are necessary to benefit understanding and approval of future therapy strategies.

Subjects

MeSH terms (MEDLINE)

Stiff-Person SyndromeImmunotherapyHumans

Author keywords

immunotherapypharmacotherapyspasmsstiffnessstiff‐person syndrome

Authors and institutions

  • Département de Neurophysiologie, Groupe Hospitalier Pitié-Salpêtrière, APHP, Paris, France.
  • French Reference Centre on Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis, Hospices Civils de Lyon, MeLiS-UCBL-CNRS UMR 5284, INSERM U1314, Université Claude Bernard Lyon 1, Lyon, France.
  • French Reference Centre for Neuromuscular Disorders, Filnemus, ERN Neuro-NMD, CHU La Timone, Aix Marseille University, Marseille, France.

ORCID profiles: Timothée Lenglet, Shahram Attarian

Funding

  • LFB

Cite

APA

Lenglet, T., Honnorat, J., & Attarian, S. (2025). Systematic Review of Immune and Symptomatic Treatments for Stiff‐Person Syndrome. European Journal of Neurology, 32(11). https://doi.org/10.1111/ene.70435

Vancouver

Lenglet T, Honnorat J, Attarian S. Systematic Review of Immune and Symptomatic Treatments for Stiff‐Person Syndrome. European Journal of Neurology. 2025;32(11). doi:10.1111/ene.70435

BibTeX
@article{Lenglet2025,
  author = {Lenglet, Timothée and Honnorat, Jérôme and Attarian, Shahram},
  title = {Systematic Review of Immune and Symptomatic Treatments for Stiff‐Person Syndrome},
  journal = {European Journal of Neurology},
  year = {2025},
  volume = {32},
  number = {11},
  doi = {10.1111/ene.70435}
}
Start for free →